Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Allani SK, Weissbach H, Lopez Toledano MA (2018) Sulindac induces differentiation of glioblastoma stem cells making them more sensitive to oxidative stress. Neoplasma 65(3):376–388. https://doi.org/10.4149/neo_2018_170404N245
2. Bakierzynska M, Cullinane MC, Redmond HP, Corrigan M (2023) Prophylactic aspirin intake and breast cancer risk; a systematic review and meta-analysis of observational cohort studies. Eur J Surg Oncol 49(10):106940. https://doi.org/10.1016/j.ejso.2023.05.015
3. Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Monk BJ (2021) Uterine serous carcinoma. Gynecol Oncol 162(1): 226–234. https://doi.org/10.1016/j.ygyno.2021.04.029
4. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, Bertagnolli MM (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res, 56(11):2556–2560.
5. Borneman, R. M., Gavin, E., Musiyenko, A., Richter, W., Lee, K. J., Crossman, D. K., . . . da Silva, L. M. (2022). Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer. J Ovarian Res, 15(1), 120. https://doi.org/10.1186/s13048-022-01050-9